Formulation reveals improved 99.5% drug release in fast-dissolving famotidine tablets, suggesting better patient compliance.
Introduction: The primary objective of this study was to formulate and evaluate fastdissolving famotidine hydrochloride tablets using an ion-exchange resin to improve patient adherence and enhance dissolution for rapid therapeutic action. Compatibility between the drug and excipients was assessed to ensure formulation stability. Methods: Drug-excipient compatibility was analyzed using FTIR spectroscopy, confirming the absence of chemical interactions. X-Ray Diffraction (XRD) analysis was employed to assess the crystalline nature of the formulations. Pre- and post-compression parameters of the tablets were evaluated in accordance with pharmacopeial standards. The Box-Behnken design was applied for formulation optimization using the desirability approach. Stability studies were conducted under accelerated conditions to determine the robustness of the optimized formulation. Results: The tablets exhibited uniform drug content, low friability, and satisfactory hardness within pharmacopeial limits. The optimized formulation showed rapid disintegration within 16 seconds and achieved 99.5% drug release within 30 minutes. Accelerated stability testing confirmed the maintenance of the drug release profile and physical characteristics for a period of two months. Conclusion: The optimized Famotidine Hydrochloride Fast-Dissolving Tablets demonstrate enhanced dissolution, rapid disintegration, and satisfactory stability. This formulation strategy offers a promising approach to improving therapeutic outcomes and patient compliance in oral drug delivery.
No takes yet. Share an insight, caveat, or question.
Praveen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: